中华肝脏病杂志最新文献

{"title":"[Current status and prospects for screening early-stage hepatocellular carcinoma].","authors":"H L Song, S F Jiang, X Yang, X X Yao, C W Pan, P Chen","doi":"10.3760/cma.j.cn501113-20240302-00105","DOIUrl":"10.3760/cma.j.cn501113-20240302-00105","url":null,"abstract":"<p><p>Hepatocellular carcinoma is the most common type of primary liver cancer. Many patients who have been diagnosed with hepatocellular carcinoma are already at an advanced stage, leading to very limited treatment options and poor prognosis. Therefore, the key to improving prognosis is early-stage diagnosis. In recent years, with deeper analysis of the underlying biological mechanisms of HCC, new diagnostic methods have emerged, including emerging serum markers, liquid biopsy, molecular diagnostics, and imaging techniques. This article reviews and analyzes the research progress on early-stage screening and explores their value and application prospects in the early predictive diagnosis of HCC..</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 1","pages":"70-76"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress in the field of liver failure and artificial liver in 2024].","authors":"T Han","doi":"10.3760/cma.j.cn501113-20241204-00611","DOIUrl":"10.3760/cma.j.cn501113-20241204-00611","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 1","pages":"13-14"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy and safety profile of TAF and TDF in vertical transmission of hepatitis B virus].","authors":"Aierkenjiang Malipati, X F Sun, X B Lu","doi":"10.3760/cma.j.cn501113-20240831-00446","DOIUrl":"10.3760/cma.j.cn501113-20240831-00446","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To retrospectively compare the efficacy and safety profile of tenofovir alafenamide fumarate (TAF) and tenofovir disoproxil fumarate (TDF) for interrupting mother-to-child transmission of hepatitis B virus (HBV). &lt;b&gt;Methods:&lt;/b&gt; A retrospective study was conducted on 97 cases of HBV-infected pregnant women. Pregnant women were divided into the TDF group (300 mg/d, &lt;i&gt;n&lt;/i&gt;=54) and the TAF group (25 mg/d, &lt;i&gt;n&lt;/i&gt;=43) and were followed up until seven months postpartum. Statistical analysis was analyzed using t-test, analysis of variance, Bonferroni test, Mann-Whitney &lt;i&gt;U&lt;/i&gt; test, or &lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; test according to different data. &lt;b&gt;Results:&lt;/b&gt; A total of 43 and 54 pregnant women received TAF and TDF treatment. There were 43 and 54 live births, respectively. Both TAF and TDF groups of pregnant women did not discontinue treatment due to adverse events. There was no statistically significant difference in alanine aminotransferase, aspartate aminotransferase, serum creatinine, and uric acid before and after treatment between the two groups. There were no outbreaks of hepatitis during treatment and follow-up among mothers in both groups. The average serum HBV DNA viral load was significantly reduced before and after treatment in both groups, and the difference was statistically significant (TAF: &lt;i&gt;F&lt;/i&gt;=40.33, &lt;i&gt;P&lt;/i&gt;&lt;0.001, TDF: &lt;i&gt;F&lt;/i&gt;=97.77, &lt;i&gt;P&lt;/i&gt;&lt;0.001), but there was no statistically significant difference in the degree of reduction between both groups (&lt;i&gt;P&lt;/i&gt;&gt;0.05). The HBeAg seronegative rates were 0.250, 0.704, and 3.743 at 28 to 32 weeks of gestation, at delivery, and seven months postpartum among pregnant women in both groups, with no statistical significance (&lt;i&gt;P&lt;/i&gt;&gt;0.05). Compared with the TDF, the levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in pregnant women in the TAF group at 28 to 32 weeks of gestation and delivery were increased, and the difference between both group was statistically significant (&lt;i&gt;P&lt;/i&gt;&lt;0.05). Compared with the baseline level, the median LDL-C level increased significantly at seven months postpartum, while the TC, TG, and HDL-C levels returned to normal, and the difference was statistically significant (&lt;i&gt;P&lt;/i&gt;&lt;0.05). There were no reports of congenital malformations or defects in all newborns at birth. The growth parameters (height, weight, head circumference) of all infants at seven months of age were within the normal range. There was no statistically significant difference between the TAF and TDF groups (&lt;i&gt;P&lt;/i&gt;&gt;0.05). The HBV DNA levels of mothers were significantly lower in both groups than the baseline during the treatment period, and there was no statistically significant difference in the magnitude of reduction between both group (&lt;i&gt;P&lt;/i&gt;&gt;0.05). All infants received HBV immunoprophylaxis, and the MTCT rate was 0. &lt;b&gt;Conclusion:&lt;/b&gt; The use of TAF in the secon","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S2","pages":"31-37"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Long-term therapeutic outcomes of antiviral treatment in patients with chronic hepatitis B infection with normal alanine aminotransferase, mild liver inflammation, and fibrosis].","authors":"Y C Shi, Y W Tan","doi":"10.3760/cma.j.cn501113-20240917-00494","DOIUrl":"10.3760/cma.j.cn501113-20240917-00494","url":null,"abstract":"<p><p><b>Objective:</b> To study the long-term prognostic outcomes of antiviral therapy in patients with chronic hepatitis B (CHB) accompanied with normal alanine aminotransferase (ALT), mild or slight inflammation, and/or liver fibrosis. <b>Methods:</b> A retrospective study method was used. Patients with CHB who underwent liver biopsy at Zhenjiang Third People's Hospital, affiliated with Jiangsu University, from January 2005 to July 2022 were included. Baseline data, clinical data, and clinical outcome events at the end of follow-up were collected. Cox proportional hazards regression and Kaplan-Meier survival analysis were used to assess the risk of clinical events. <b>Results:</b> A total of 149 CHB cases with normal ALT with mild or slight inflammation or fibrosis were included. Eighty-six cases were treated with antiviral therapy, while 63 were not. The median follow-up time was 82.00 (45.50,153.00) months. In the follow-up endpoint events, four cases (4.65%, 4/86) in the antiviral group had liver cirrhosis, while none had progressed to hepatocellular carcinoma. Five cases (7.94%, 5/63) in the non-antiviral group had liver cirrhosis, and two cases (3.17%, 2/63) had hepatocellular carcinoma. Kaplan-Meier survival analysis showed that the cumulative risk of clinical events did not significantly increase in the non-antiviral group (<i>P</i>>0.05). The presence of liver fibrosis with high-normal ALT levels at baseline were associated with an increased risk of clinical events (<i>P</i><0.05). Cox analysis showed that baseline age, high ALT level, and presence of liver fibrosis were independent risk factors for clinical events. The two groups differed significantly in terms of the proportion of HBVDNA below the detection value and ALT normalization rate at the endpoint (<i>P</i><0.05). However, there was no significant difference in the HBsAg negative conversion rate between the two groups at the end (<i>P</i>>0.05). <b>Conclusion:</b> The occurrence risk of long-term liver adverse events was not significantly improved by antiviral treatment in patients with chronic hepatitis B accompanied by normal ALT levels, mild or slight inflammation, and/or liver fibrosis. However, clinical outcomes were associated with baseline age, higher ALT levels, and liver fibrosis, suggesting that these factors are independent risk factors for the occurrence of clinical events.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S2","pages":"8-13"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Current status of genotyping of pregnant women with hepatitis C and its impact on pregnancy outcomes].","authors":"M Cai, Y Ding, Q X Li, Y L Jiang, Y W Zhang, X Yue","doi":"10.3760/cma.j.cn501113-20240821-00378","DOIUrl":"10.3760/cma.j.cn501113-20240821-00378","url":null,"abstract":"<p><p><b>Objective:</b> To understand the current genotype distribution, epidemiological characteristics, and their relationship with pregnancy outcomes in pregnant women with hepatitis C in Nanjing city. <b>Methods:</b> An epidemiological survey method was used to analyze the data of 113 pregnant women with hepatitis C who were successfully genotyped and admitted to Nanjing Second Hospital from January 2018 to December 2023. The comparison of the quantitative data was analyzed by a t-test or rank-sum test between the two groups. The comparison of the enumeration data was analyzed using the <i>χ</i>² test, adjusted <i>χ</i>² test, or Fisher's exact probability method between the two groups. <b>Results:</b> A total of six kinds of genotypes (1b, 2a, 3a, 3b, 6a, 6n) were identified in 113 cases. The primary genotype was 1b (accounted for 76.1%), followed by 6, 3, and 2 rare genotypes, while 1 mixed type (type 2 mixed with type 6) and genotypes 4 and 5 were non-identified. The proportion of genotype 1b increased with the extension of the birth cohort, and the difference was statistically significant (<i>χ</i>²=24.35, <i>P</i>＜0.001). There was a difference in genotyping proportions with educational and employment background (<i>χ</i>²=14.74, <i>P</i>＜0.001; <i>χ</i>²=19.50, <i>P</i>＜0.001). The proportion of non-1b types increased in populations with low educational backgrounds and unemployment. The proportion of type 1b was higher in those with a history of blood transfusion and hospitalization during infancy (<i>χ</i>²=5.57, <i>P</i>=0.018; <i>χ</i>²=5.17, <i>P</i>=0.023). The proportion of non-1b type was higher in those with a history of drug abuse (<i>χ</i>²=22.32, <i>P</i>＜0.001). Normal pregnancy outcomes had no statistically significant difference between genotype 1b and non-1b groups. However, all pregnant women who experienced adverse infant outcomes had genotype 1b. <b>Conclusion:</b> Pregnant women with hepatitis C in Nanjing city are mainly genotype 1b, with genotype 3b<5%, and there is no significant difference in maternal and infant outcomes among different genotype subtypes. Therefore, no testing of genotype for women of childbearing age. However, the focus should be on the management of pregnancy, health education, and postpartum preparation for direct acting antiviral treatment.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S2","pages":"21-24"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Emphasis on scientific research related to viral hepatitis].","authors":"H Ren, P Hu","doi":"10.3760/cma.j.cn501113-20241127-00600","DOIUrl":"10.3760/cma.j.cn501113-20241127-00600","url":null,"abstract":"<p><p>The Chinese Journal of Hepatology second supplementary issue in 2024 focused on viral hepatitis. The context of hepatitis B and C encompassed the exploration of expanding treatment advantages, research on the treatment of special populations, the clinical cure concept, and the regional and special population genotyping, treatment of patients who failed to receive direct-acting antiviral drugs, and medical prevention and elimination fusion models. The supplement's findings reflect the current trends in prevention and treatment, such as epidemiology, clinical practice, and elimination models, and serve as references for exploring antiviral treatment plans and hepatitis elimination models, assisting readers to experience the academic dynamism of liver disease, address elimination challenges, and facilitate goal attainment.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S2","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Study on hepatitis C intervention measures to improve the referral, treatment, and cure rate in hospitals].","authors":"H H Cheng, D C Cai","doi":"10.3760/cma.j.cn501113-20241017-00544","DOIUrl":"10.3760/cma.j.cn501113-20241017-00544","url":null,"abstract":"<p><p><b>Objective:</b> To explore and discuss hepatitis C processes of diagnosis, treatment, and management through intervention measures as well as the necessity of whole management attempt in education, screening, diagnosis, treatment, and follow-up in hospitals. <b>Method:</b> The baseline status of HCV RNA detection, departmental distribution, consultation requests, specialist visits, and diagnosis and treatment of anti-HCV positive patients who visited the outpatient and inpatient departments of the Infectious Diseases of the Second Affiliated Hospital of Chongqing Medical University from November 2019 to November 2020 was analyzed. Statistical analysis was re-conducted on the status of HCV RNA detection, departmental distribution, consultation requests, specialist visits, and treatment among anti-HCV positive patients following the implementation of intervention measures for patients and clinicians in the hospital. The differences were evaluated using the Pearson chi-square test. The Wilson score and the gamma distribution method were used to calculate the 95% confidence interval (95% <i>CI</i>). <b>Results:</b> The rates of consultation, referral, diagnosis, and treatment did not increase significantly following the intervention in the hospital for hepatitis C, and there was no statistically significant difference compared with the data before the intervention. <b>Conclusion:</b> The vast majority of anti-HCV-positive patients in non-infectious and a few infectious disease departments did not receive timely disease assessment, referral, diagnosis, and treatment because hospitals lacked a standard, consistent, and stringent whole management process for hepatitis C screening, thereby causing missed detection, diagnosis, and treatment.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S2","pages":"38-43"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Exploring the harm elimination model with regard to viral hepatitis C in China's western region].","authors":"X Wu, Y Yang, Q Cao, L S Gan, G H Wu, D C Cai","doi":"10.3760/cma.j.cn501113-20241103-00564","DOIUrl":"10.3760/cma.j.cn501113-20241103-00564","url":null,"abstract":"<p><p>Hepatitis C virus (HCV) infection, a kind of infectious disease that poses a major threat to human health, has attracted widespread attention worldwide. The prevention and control of hepatitis C are especially challenging in China's western region due to the complexity of the geographical background, the relatively backward economic development level, and the diversity of cultural background. The main purpose of this paper is to deeply explore the harm elimination model for hepatitis C in China's western region through a detailed analysis of the current epidemic status, an in-depth discussion of its harm, and a comprehensive evaluation of prevention and control strategies, combined with the specific characteristics so as to propose a practical elimination model and specific measures. Additionally, we aspire to provide valuable references and concepts for the prevention and control on national scale through these studies recommendations, thereby effectively reducing the threat of the hepatitis C virus to human health..</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S2","pages":"63-67"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A case of chronic hepatitis B patient with sequential treatment of tenofovir and pegylated interferon alpha].","authors":"Z Huang, Y P Wang, J P Li","doi":"10.3760/cma.j.cn501113-20240926-00507","DOIUrl":"10.3760/cma.j.cn501113-20240926-00507","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S2","pages":"44-47"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A clinically cured case of chronic hepatitis B].","authors":"Y Q Zhang, Z Y Zhang, X X Li, M H Li","doi":"10.3760/cma.j.cn501113-20241001-00524","DOIUrl":"10.3760/cma.j.cn501113-20241001-00524","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S2","pages":"50-53"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}